Hyperlipidemia
📧 Sign up to get email alerts when something new happens for Hyperlipidemia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2014-12-01FDA Approved: LOVASTATIN — Supplemental Application (Carlsbad Technology, Inc.)
FDA approved a supplemental application for Lovastatin from Carlsbad Technology, Inc., expanding access to a generic statin.
-
FDA approval · 2014-11-25FDA Approved: SIMVASTATIN — Original Application (XLCare Pharmaceuticals Inc.)
The FDA approved the original application for SIMVASTATIN from XLCare Pharmaceuticals Inc., granting marketing authorization for a generic s…
-
CLINICAL_TRIALS research · 2014-11-24Clinical Trial Update: Comparison of LDL Particle Count With Other Available Lipid Tests
This document provides an update on a clinical trial comparing LDL particle count with other lipid tests in hyperlipidemia, sponsored by Scr…
-
CLINICAL_TRIALS trial_result · 2014-11-21Clinical Trial Update: Effect of Cheese on Cardiovascular Risk [NA]
A University of Copenhagen trial evaluating cheese consumption and cardiovascular risk in individuals with hyperlipidemia has completed.
-
FDA approval · 2014-11-05FDA Approved: SIMVASTATIN — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare, Inc.'s supplemental application for simvastatin (generic statin).
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-11-05FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for atorvastatin calcium (generic) from Dr. Reddy's Laboratories Limited. This document confirms the…
-
FDA approval · 2014-11-05FDA Approved: SIMVASTATIN — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for simvastatin submitted by NorthStar Rx LLC.
-
FDA approval · 2014-11-05FDA Approved: SIMVASTATIN — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s supplemental application for simvastatin, updating the approved generic product.
-
FDA approval · 2014-11-04FDA Approved: SIMVASTATIN — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for simvastatin by Micro Labs Limited under ANDA090383, updating the regulatory status of the approv…
-
FDA approval · 2014-11-04FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for atorvastatin calcium from Dr. Reddy's Laboratories Limited, confirming approval of a generic ato…
-
FDA approval · 2014-11-03FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for fenofibrate, confirming approval of a generic fenofibrate product.
-
FDA approval · 2014-11-03FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for pravastatin sodium from Dr. Reddy's Laboratories Limited.
-
FDA approval · 2014-11-03FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for pravastatin sodium, indicating regulatory approval for changes to this …
-
FDA approval · 2014-10-31FDA Approved: FENOFIBRATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic fenofibrate under an Original Application.
-
CLINICAL_TRIALS trial_result · 2014-10-30Clinical Trial Update: Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
This clinical trial update reports the proportion of secondary prevention patients who achieved their LDL-C targets.
-
CLINICAL_TRIALS trial_result · 2014-10-30Clinical Trial Update: Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
AstraZeneca-sponsored clinical trial update reports the percentage of secondary prevention patients who achieved their LDL-C targets in the …
-
CLINICAL_TRIALS research · 2014-10-30Clinical Trial Update: Diabetic Under 70 (Diabetics Below 70)
AstraZeneca-sponsored clinical trial has completed, involving participants with diabetes and hyperlipidemia, with atherosclerosis also liste…
-
FDA approval · 2014-10-26FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves a supplemental application for ATORVASTATIN CALCIUM from Mylan Pharmaceuticals Inc., granting approval of a generic atorvastati…
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation [Phase 2]
Phase 2 clinical study evaluating the antihyperlipidemic effects of a classical Unani antiobesity formulation in hyperlipidemia; the study s…
-
CLINICAL_TRIALS trial_result · 2014-10-21Clinical Trial Update: Study of Medical Assistant Health Coaching in Primary Care for Patients With Chronic Conditions [NA]
Clinical trial update on a study evaluating medical assistant health coaching in primary care for patients with chronic conditions (diabetes…
-
CLINICAL_TRIALS research · 2014-10-20Clinical Trial Update: Acupuncture and Moxibustion for Hyperlipemia [NA]
A clinical trial update describes acupuncture and moxibustion as a potential treatment for hyperlipidemia, with unknown phase and status.
-
FDA approval · 2014-10-16FDA Approved: PRAVASTATIN SODIUM — Supplemental Application (CIPLA USA INC.)
The FDA approved Cipla USA Inc.'s supplemental application for pravastatin sodium, confirming approval of a generic pravastatin product.
-
CLINICAL_TRIALS trial_result · 2014-10-16Clinical Trial Update: Long Term Antihypertensive Exposure and Adverse Metabolic Effects: PEAR Follow-Up Study [Phase 4]
Phase 4 follow-up trial assessing long-term antihypertensive exposure and its metabolic adverse effects, including drug-induced hyperglycemi…
-
CLINICAL_TRIALS trial_result · 2014-10-10Clinical Trial Update: Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy [Phase 3]
Phase 3 trial evaluating lipid changes and safety of raltegravir in HIV-infected patients with hyperlipidemia on current standard therapy. T…
-
FDA approval · 2014-10-09FDA Approved: COLESTIPOL HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals of New York LLC)
The FDA approved a supplemental application for Colestipol hydrochloride by Amneal Pharmaceuticals of New York LLC.